Does the media favor GEHC or LQDA?

In the previous week, GE HealthCare Technologies had 32 more articles in the media than Liquidia. MarketBeat recorded 57 mentions for GE HealthCare Technologies and 25 mentions for Liquidia. GE HealthCare Technologies' average media sentiment score of 0.73 beat Liquidia's score of 0.69 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 23 Very Positive mention(s) 8 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LQDA or PHG?

Liquidia currently has a consensus target price of $86.18, indicating a potential upside of 2.46%. Given Liquidia's stronger consensus rating and higher possible upside, research analysts plainly believe Liquidia is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liquidia 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 2.82 Koninklijke Philips 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Which has stronger earnings and valuation, LQDA or PHG?

Koninklijke Philips has higher revenue and earnings than Liquidia. Koninklijke Philips is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 47.25 -$68.92M $0.14 600.79 Koninklijke Philips $20.17B 1.28 $1.01B $1.36 19.33

Does the media refer more to LQDA or PHG?

In the previous week, Liquidia had 8 more articles in the media than Koninklijke Philips. MarketBeat recorded 25 mentions for Liquidia and 17 mentions for Koninklijke Philips. Liquidia's average media sentiment score of 0.69 beat Koninklijke Philips' score of 0.55 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Koninklijke Philips 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ZBH or LQDA?

Zimmer Biomet has higher revenue and earnings than Liquidia. Zimmer Biomet is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.21 $705.20M $3.85 24.47 Liquidia $158.32M 47.25 -$68.92M $0.14 600.79

Is ZBH or LQDA more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Zimmer Biomet's return on equity. Company Net Margins Return on Equity Return on Assets Zimmer Biomet 9.05% 13.24% 7.28% Liquidia 7.74% 46.82% 7.06%

Does the media prefer ZBH or LQDA?

In the previous week, Liquidia had 5 more articles in the media than Zimmer Biomet. MarketBeat recorded 25 mentions for Liquidia and 20 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.86 beat Liquidia's score of 0.69 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 11 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LQDA or SOLV?

Solventum has higher revenue and earnings than Liquidia. Solventum is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 47.25 -$68.92M $0.14 600.79 Solventum $8.33B 1.78 $1.56B $8.16 10.50

Is LQDA or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Solventum's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% Solventum 17.33% 23.51% 7.63%

Does the media refer more to LQDA or SOLV?

In the previous week, Liquidia had 14 more articles in the media than Solventum. MarketBeat recorded 25 mentions for Liquidia and 11 mentions for Solventum. Solventum's average media sentiment score of 0.86 beat Liquidia's score of 0.69 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SNN or LQDA?

Smith & Nephew SNATS has higher revenue and earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.16 $625M N/A N/A Liquidia $158.32M 47.25 -$68.92M $0.14 600.79

Does the media prefer SNN or LQDA?

In the previous week, Liquidia had 23 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 25 mentions for Liquidia and 2 mentions for Smith & Nephew SNATS. Liquidia's average media sentiment score of 0.69 beat Smith & Nephew SNATS's score of 0.00 indicating that Liquidia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Liquidia (LQDA) Competitors

$84.11 -2.69 (-3.10%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$83.59 -0.52 (-0.62%)

As of 07/31/2026 07:58 PM Eastern

Compare

LQDA vs. GEHC, PHG, ZBH, SOLV, and SNN

Should you buy Liquidia stock or one of its competitors? MarketBeat compares Liquidia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liquidia include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN).

How does Liquidia compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GE HealthCare Technologies has a net margin of 9.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.33%	20.12%	5.74%
Liquidia	7.74%	46.82%	7.06%

GE HealthCare Technologies has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

GE HealthCare Technologies currently has a consensus price target of $77.73, suggesting a potential upside of 14.27%. Liquidia has a consensus price target of $86.18, suggesting a potential upside of 2.46%. Given GE HealthCare Technologies' higher probable upside, equities analysts clearly believe GE HealthCare Technologies is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

GE HealthCare Technologies has higher revenue and earnings than Liquidia. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$21.27B	1.45	$2.08B	$4.36	15.60
Liquidia	$158.32M	47.25	-$68.92M	$0.14	600.79

In the previous week, GE HealthCare Technologies had 32 more articles in the media than Liquidia. MarketBeat recorded 57 mentions for GE HealthCare Technologies and 25 mentions for Liquidia. GE HealthCare Technologies' average media sentiment score of 0.73 beat Liquidia's score of 0.69 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	23 Very Positive mention(s)	8 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GE HealthCare Technologies beats Liquidia on 10 of the 17 factors compared between the two stocks.

How does Liquidia compare to Koninklijke Philips?

Liquidia (NASDAQ:LQDA) and Koninklijke Philips (NYSE:PHG) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Liquidia had 8 more articles in the media than Koninklijke Philips. MarketBeat recorded 25 mentions for Liquidia and 17 mentions for Koninklijke Philips. Liquidia's average media sentiment score of 0.69 beat Koninklijke Philips' score of 0.55 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Liquidia has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Liquidia currently has a consensus target price of $86.18, indicating a potential upside of 2.46%. Given Liquidia's stronger consensus rating and higher possible upside, research analysts plainly believe Liquidia is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Koninklijke Philips	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Liquidia has a net margin of 7.74% compared to Koninklijke Philips' net margin of 6.30%. Liquidia's return on equity of 46.82% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Koninklijke Philips	6.30%	14.38%	5.96%

Koninklijke Philips has higher revenue and earnings than Liquidia. Koninklijke Philips is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	47.25	-$68.92M	$0.14	600.79
Koninklijke Philips	$20.17B	1.28	$1.01B	$1.36	19.33

Summary

Liquidia beats Koninklijke Philips on 13 of the 17 factors compared between the two stocks.

How does Liquidia compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Liquidia had 5 more articles in the media than Zimmer Biomet. MarketBeat recorded 25 mentions for Liquidia and 20 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.86 beat Liquidia's score of 0.69 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	11 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Liquidia. Zimmer Biomet is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.21	$705.20M	$3.85	24.47
Liquidia	$158.32M	47.25	-$68.92M	$0.14	600.79

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zimmer Biomet presently has a consensus target price of $102.00, suggesting a potential upside of 8.28%. Liquidia has a consensus target price of $86.18, suggesting a potential upside of 2.46%. Given Zimmer Biomet's higher probable upside, equities analysts plainly believe Zimmer Biomet is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.24
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

Zimmer Biomet has a net margin of 9.05% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Liquidia	7.74%	46.82%	7.06%

Summary

Zimmer Biomet beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Solventum?

Liquidia (NASDAQ:LQDA) and Solventum (NYSE:SOLV) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Solventum has a net margin of 17.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Solventum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Solventum	17.33%	23.51%	7.63%

In the previous week, Liquidia had 14 more articles in the media than Solventum. MarketBeat recorded 25 mentions for Liquidia and 11 mentions for Solventum. Solventum's average media sentiment score of 0.86 beat Liquidia's score of 0.69 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has higher revenue and earnings than Liquidia. Solventum is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	47.25	-$68.92M	$0.14	600.79
Solventum	$8.33B	1.78	$1.56B	$8.16	10.50

Liquidia has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

64.5% of Liquidia shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liquidia currently has a consensus target price of $86.18, suggesting a potential upside of 2.46%. Solventum has a consensus target price of $86.00, suggesting a potential upside of 0.36%. Given Liquidia's stronger consensus rating and higher probable upside, equities analysts clearly believe Liquidia is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Liquidia beats Solventum on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Smith & Nephew SNATS presently has a consensus price target of $30.93, suggesting a potential downside of 1.92%. Liquidia has a consensus price target of $86.18, suggesting a potential upside of 2.46%. Given Liquidia's stronger consensus rating and higher probable upside, analysts plainly believe Liquidia is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Liquidia has a net margin of 7.74% compared to Smith & Nephew SNATS's net margin of 0.00%. Liquidia's return on equity of 46.82% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Liquidia	7.74%	46.82%	7.06%

In the previous week, Liquidia had 23 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 25 mentions for Liquidia and 2 mentions for Smith & Nephew SNATS. Liquidia's average media sentiment score of 0.69 beat Smith & Nephew SNATS's score of 0.00 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.16	$625M	N/A	N/A
Liquidia	$158.32M	47.25	-$68.92M	$0.14	600.79

Smith & Nephew SNATS has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Liquidia beats Smith & Nephew SNATS on 12 of the 15 factors compared between the two stocks.

Get Liquidia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LQDA vs. The Competition

Export

Metric	Liquidia	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.72B	$12.82B	$7.22B	$12.30B
Dividend Yield	N/A	2.72%	2.59%	9.45%
P/E Ratio	600.83	793.97	280.89	24.67
Price / Sales	47.25	935.38	639.94	110.49
Price / Cash	N/A	76.57	71.02	59.62
Price / Book	164.92	10.88	11.07	5.90
Net Income	-$68.92M	$2.82B	$3.49B	$336.16M
7 Day Performance	-2.45%	-0.19%	-0.24%	0.08%
1 Month Performance	6.04%	-3.32%	-2.98%	-5.67%
1 Year Performance	375.74%	155.35%	61.99%	18.82%

Liquidia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LQDA Liquidia	3.063 of 5 stars	$84.11 -3.1%	$86.18 +2.5%	+350.0%	$7.72B	$158.32M	600.83	50	Insider Trade
GEHC GE HealthCare Technologies	4.6286 of 5 stars	$61.12 +0.9%	$76.41 +25.0%	-4.6%	$27.56B	$20.63B	14.62	54,000	Trending News Earnings Report Analyst Forecast Options Volume Gap Up
PHG Koninklijke Philips	2.4856 of 5 stars	$25.06 -4.3%	N/A	+0.5%	$25.72B	$20.17B	21.47	65,340	High Trading Volume
ZBH Zimmer Biomet	2.9836 of 5 stars	$92.15 +0.9%	$100.70 +9.3%	+2.8%	$17.67B	$8.23B	23.93	17,000	Upcoming Earnings Analyst Forecast
SOLV Solventum	2.9674 of 5 stars	$80.49 +3.2%	$81.91 +1.8%	+20.1%	$13.51B	$8.26B	9.86	20,000	Positive News Upcoming Earnings Analyst Upgrade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LQDA) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liquidia (LQDA) Competitors

LQDA vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Liquidia compare to GE HealthCare Technologies?

Summary

How does Liquidia compare to Koninklijke Philips?

Summary

How does Liquidia compare to Zimmer Biomet?

Summary

How does Liquidia compare to Solventum?

Summary

How does Liquidia compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liquidia (LQDA) Competitors

LQDA vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Liquidia compare to GE HealthCare Technologies?

Do insiders and institutionals hold more shares of GEHC or LQDA?

Is GEHC or LQDA more profitable?

Which has more volatility & risk, GEHC or LQDA?

Do analysts prefer GEHC or LQDA?

Which has higher valuation & earnings, GEHC or LQDA?

Does the media favor GEHC or LQDA?

Summary

How does Liquidia compare to Koninklijke Philips?

Does the media refer more to LQDA or PHG?

Do insiders and institutionals have more ownership in LQDA or PHG?

Which has more risk & volatility, LQDA or PHG?

Do analysts prefer LQDA or PHG?

Is LQDA or PHG more profitable?

Which has stronger earnings and valuation, LQDA or PHG?

Summary

How does Liquidia compare to Zimmer Biomet?

Does the media prefer ZBH or LQDA?

Which has more volatility & risk, ZBH or LQDA?

Which has preferable earnings and valuation, ZBH or LQDA?

Do institutionals and insiders have more ownership in ZBH or LQDA?

Do analysts recommend ZBH or LQDA?

Is ZBH or LQDA more profitable?

Summary

How does Liquidia compare to Solventum?

Is LQDA or SOLV more profitable?

Does the media refer more to LQDA or SOLV?

Which has preferable valuation & earnings, LQDA or SOLV?

Which has more volatility and risk, LQDA or SOLV?

Do institutionals & insiders hold more shares of LQDA or SOLV?

Do analysts recommend LQDA or SOLV?

Summary

How does Liquidia compare to Smith & Nephew SNATS?

Do analysts rate SNN or LQDA?

Do insiders and institutionals have more ownership in SNN or LQDA?

Is SNN or LQDA more profitable?

Does the media prefer SNN or LQDA?

Which has higher earnings & valuation, SNN or LQDA?

Which has more volatility and risk, SNN or LQDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools